Self-assembling nanoparticles for miRNA delivery towards precision medicine against melanoma

Le résumé fourni par la source

Metastatic melanoma is a highly aggressive tumor with a poor prognosis. One of the therapeutic options for patients bearing BRAF V600E mutations is targeted therapy, which is based on the use of drugs able to inhibit the mitogen-activated protein kinase (MAPK) pathway. However, the long-term efficacy of targeted therapy is compromised by the onset of drug resistance. We previously identified a panel of oncosuppressor microRNAs (miRNAs) able to prevent the development of drug resistance to targeted therapy. We also developed self-assembling nanoparticles (SANP) as a promising and versatile nanomedicine platform for RNA-based personalized therapies. Here, we provide the proof-of-principle of a miRNA-based therapeutic strategy against BRAF-mutant melanomas. The role of the cationic lipid, ionizable lipid, cholesterol, and PEGylated lipid in SANP formulations was investigated to optimize miRNA encapsulation and delivery to melanoma cells. miRNA-loaded SANPs inhibited the release of soluble tumor-promoting factors and prevented the proliferation of metastatic melanoma cells. When used in combination with targeted therapy, miRNA-SANPs were able to potentiate its efficacy in a dose-response manner. These results pave the way for further studies on SANP as a platform for miRNA delivery to prevent the development of resistance to targeted therapy in metastatic melanoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.